Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients
PHASE1CompletedINTERVENTIONAL
Enrollment
13
Participants
Timeline
Start Date
April 30, 2016
Primary Completion Date
July 31, 2016
Study Completion Date
July 31, 2016
Conditions
End Stage Renal Disease
Interventions
DRUG
Triferic
Trial Locations (1)
32809
Orlando Clinical Research Center, Orlando
All Listed Sponsors
lead
Rockwell Medical Technologies, Inc.
INDUSTRY
NCT02739100 - Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients | Biotech Hunter | Biotech Hunter